Related Experiment Video
Updated: Aug 5, 2026
06:19
Constructing and Visualizing Models using Mime-based Machine-learning Framework
Published on: July 22, 2025
MuTATE: an interpretable multi-endpoint machine learning framework for automated molecular subtyping in cancer
Sarah G Ayton1,2,3,4, Martina Pavlicova5, Carla Daniela Robles-Espinoza6,7
1Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico. sarah.ayton@columbia.edu.
Npj Health Systems
|July 29, 2026
Summary
MuTATE, a machine learning (ML) framework, enhances cancer subtyping and risk stratification. It offers improved accuracy and interpretability over traditional models, aiding precision oncology.
Area of Science:
- Oncology
- Bioinformatics
- Computational Biology
Background:
- Effective molecular subtyping is crucial for cancer risk stratification and treatment, but current methods have limitations.
- Traditional models struggle with multiple clinical endpoints, and machine learning (ML) approaches often lack transparency.
- Existing methods limit prognostic utility and hinder the integration of advanced analytics in precision oncology.
Purpose of the Study:
- To develop an automated, interpretable decision-tree framework (MuTATE) powered by ML for improved cancer subtyping and multi-endpoint risk stratification.
- To enhance accuracy, interpretability, and biomarker discovery in cancer subtyping.
- To enable scalable integration of multi-endpoint ML into precision oncology workflows.
Main Methods:
- Developed MuTATE, an automated, interpretable decision-tree framework utilizing ML.
- Evaluated MuTATE using 18,400 simulations and 682 patient biopsies from The Cancer Genome Atlas (TCGA) datasets.
- Compared MuTATE's performance against established clinical models in lower-grade glioma (LGG), endometrial carcinoma (EC), and gastric adenocarcinoma (GA).
Main Results:
- MuTATE demonstrated improved accuracy, interpretability, and biomarker discovery compared to established clinical models.
- Significant reclassification of risk groups was observed across LGG, GA, and EC patient cohorts.
- In LGG, MuTATE reclassified 13% of "low-risk" IDH-1p19q cases and 19% of "high-risk" IDH wild-type cases.
- In GA, MuTATE identified a higher-risk ARID1A wild-type subtype within the "intermediate-risk" genomically stable group.
- In EC, 72% of "intermediate-risk" MSI/MLH1 cases were reassigned to the highest-risk category.
Conclusions:
- MuTATE offers a powerful tool for reducing diagnostic bias and improving cancer risk stratification.
- The framework enhances the integration of multi-endpoint ML into precision oncology, supporting personalized treatment strategies.
- MuTATE's interpretability and accuracy hold significant potential for advancing cancer diagnostics and patient management.
